ORIGINAL ARTICLE

ANTI-INFLAMMATORY ACTIVITY OF H1 RECEPTOR ANTAGONIST CETIRIZINE IN ANIMAL MODELS
Vardhamane S. H, Jeevangi Santoshkumar

1. Professor. Department of Pharmacology, MR Medical College, Gulbarga, Karnataka.
2. Associate Professor, Department of Pharmacology, MR Medical College, Gulbarga, Karnataka.

CORRESPONDING AUTHOR:
Vardhamane S. H,
Professor Pharmacology,
MR Medical College, Gulbarga,
Karnataka.
E-mail: drshvardhamane@gmail.com

ABSTRACT: AIM: The present study was designed to study anti-inflammatory activity of Cetirizine in albino rats and compare with standard drug Diclofenac. MATERIAL & METHODS: 1. Carrageenin induced rat paw edema method (Acute inflammation): 5 animals in each group (3groups) received orally 4% Gum acacia, Diclofenac sodium and Cetirizine respectively one hour before carrageenin injection into right paw. The rat paw edema was measured with plethysmograph after 3 hours and percentage inhibition of edema was calculated in each group. 2. Rexin pellet granuloma method (Chronic inflammation): Four rexin pellets were implanted into dorsum skin of each rat of 3 groups (n=5), which include control, Diclofenac and Cetirizine respectively. The animals were treated with fixed doses of drugs once a day for 7 days including the day of implantation of pellets and on 8th day rexin pellets were removed after sacrificing animals. Rexin pellets were kept in incubator at 60°C overnight. Pellets were then weighed and percent inhibition of granuloma tissue was calculated. 3. Study of Mast cell counts. RESULT: Cetirizine showed significant anti-inflammatory activity both in acute and chronic animal models. CONCLUSION: Cetirizine may be used as potential drug for both acute and chronic inflammation due to its anti-inflammatory property.

KEY WORDS: Cetirizine, Diclofenac, Anti-inflammatory, Mast cell count, Rat paw edema, Rexin pellet granuloma.

INTRODUCTION: Inflammation is a complex reaction in vascularized connective tissue, which is elicited by the same exogenous and endogenous stimuli causing cell injury. The term “inflammation” is derived from the Latin literature and the Greek “Phlegmasia”. Although inflammation helps in clearing infection and wound healing, both inflammation and repair have tremendous potential to cause harm

1. Inflammation may contribute to a variety of disease that are not thought to be primarily due to abnormal host response. For instance, chronic inflammation may play a role in Atherosclerosis, Rheumatoid arthritis, Type -2 diabetes, Alzheimer disease and Cancer

2. Histamine is a naturally occurring amine stored within the body and is capable of eliciting major changes in a variety of body functions. Histamine is stored in mast cells

3. The concentration of histamine is particularly rich in tissues that contain large number of mast cells such as skin, mucosa of bronchial tree and intestinal mucosa. H1 receptors are found in smooth muscles, endothelial cells, adrenal medulla, heart and CNS

4. Histamine plays a major role in acute inflammation by causing an increase in vascular permeability and vasodilatation which allows general egress of white blood cells into the
extravascular space. The potential importance of the interaction of mediators was first
developed based upon the synergism between vasodilator prostaglandins and factors which
increase micro vascular permeability and subsequently extended to include non-prostaglandin
vasodilators. It also causes pain and itching and act as chemotactic especially for eosinophil.
The role of histamine in acute inflammation associated with mast cell degranulation in non-
rodent species including man where as its role in chronic inflammation is yet to be established. Cetirizine is used for seasonal allergic rhinitis in children aged 2-6 years. The anti-
inflammatory effect of cetirizine is similar to that of ibuprofen. The effect of cetirizine on human
eosinophils from patients with allergic rhinitis was studied in vitro by Sedgwick and Busse. Other studies also demonstrated that high concentrations (~100 µmol/l) of cetirizine were
required to achieve eosinophil inhibition in vitro. In contrast, some investigations reported
significant eosinophil inhibition in vitro at cetirizine concentrations within the therapeutic
range, i.e. at 0.1 µg/ml and cetirizine inhibition of monocytes and T cells in vitro with 0.25-2.5
µg/ml.

Evidence suggests that the continual release of histamine from lung cells of asthma
patients may contribute to lung tissue inflammation and remodeling and may affect
lymphocytes, monocytes, basophils, epithelial cells, and macrophages by modulating the release
of pro-inflammatory and immune-regulatory mediators and cytokines. The anti-
inflammatory activities of second- and third-generation H1-receptor antagonists have been
evaluated in vitro. These studies have shown that many second-generation H1-receptor
antagonists (considered potentially or minimally sedating) and third-generation H1-receptor
antagonists (considered non-sedating) inhibit release or generation of multiple inflammatory
mediators, including IL-4, IL-6, IL-8, and IL-13; PGD2; LTC4; tryptase; histamine; and the TNF-α-
induced chemokine RANTES, as well as eosinophil chemotaxis and adhesion.

Carrageein induced hind paw inflammation is a neutrophil-mediated acute
inflammatory response that produce hind paw swelling, erythema and localized hyperthermia. Free radicals play an important role in the pathogenesis of inflammation. Keeping in view of the above ideas, the present study has been undertaken to evaluate the anti-
inflammatory activity of newer non-sedative H1 receptor blocker cetirizine on the acute and
chronic inflammatory models in albino rats.

MATERIALS AND METHODS: The present study was conducted in the Department of
Pharmacology, Mahadevappa Rampure Medical College, Gulbarga, Karnataka, after taking
permission from the Institution Ethics Committee and Animal Ethics Committee of M.R. Medical
College, Gulbarga, Karnataka.
Drugs used in the study:
1. Cetirizine dihydrochloride: M/S Recon Ltd Bangalore.
2. Vehicle: Normal Saline (0.9%) local purchase.
3. Gum Acacia: local purchase.
4. Diclofenac sodium: Pure powder obtained Biocon Pharmaceuticals, Bangalore.
5. Carrageenin: 1%, INCO, Ambala.

STUDY DESIGN: Albino rats of either sex weighing 150-200g were used. Total 30 rats were
selected and were divided into 3 groups of 5 each for Acute and Chronic animal models. The rats
were obtained from the Central Animal House of M.R. Medical College, Gulbarga. Before starting
the study, the animals were allowed to acclimatize to the laboratory environment for one week and they were provided with standard diet and water ad libitum as per recommendation of (CPCSEA) “Committee for the purpose of control and supervision of experiments on animals”, Government of India (Reg. No.142/99, dated 11-07-1999/CPCSEA.) for laboratory animal facilities17, 18.

1. Rat Paw edema method:
a. Group 1 (Control): 4% Gum Acacia, 2ml/kg.
b. Group 2 (Standard Drug): Diclofenac sodium (4.5mg/kg) in 4% Gum Acacia.
c. Group 3 (Test Drug): Cetirizine 900µg/kg in 4% Gum Acacia.
All the drugs were administered orally and followed by a constant volume of distilled water after each administration to ensure the entry of drug. One hour after feeding, each rat is anaesthetized with ether and under anesthesia 0.1ml of 1% Carrageenin is injected into sub-plantar region of the hind paw of the rat and the volume of paw is measured by Plethysmograph before and after injection of 1% carrageenin19. Volume of edema is recorded at the end of 3 hours after Carrageenin administration. Same procedure was adopted for rats of all the groups (Photograph 1 and Photograph 2).
The percent inhibition of edema in drug treated rats (standard and test drugs) is calculated by using the formula.
Percent inhibition = \( \frac{V_c - V_t}{V_t} \times 100 \)
Where,
\( V_c = \) Volume of paw edema in control animals
\( V_t = \) Volume of paw edema in drug treated animals.
The dose of the drug under study was calculated by using the dose conversion table.

Table No.1: Dose Conversion table20.

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Human (70kg)</th>
<th>Conversion factor</th>
<th>Dose for Rat (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose(mg/kg)</td>
<td>Rat</td>
<td>Per kg body weight (1000gms)</td>
</tr>
<tr>
<td>Diclofenac sodium</td>
<td>50</td>
<td>0.018</td>
<td>0.9</td>
</tr>
<tr>
<td>Cetirizine dihydrochloride</td>
<td>10</td>
<td>0.018</td>
<td>0.18</td>
</tr>
</tbody>
</table>

2. Rexin pellet granuloma method21.
Discs of equal size and weight were punched out from rexin sheet. Two such discs were stitched together with their rough surface exposed outside and rexin covered surfaces facing each other. Rexin pellets were sterilized using 70% ethyl alcohol. Adult albino rats, 15 in number of either sex weighing about 150 to 200gms, were selected and divided into 3 groups of 5 animals each. The first group served as a control and was given 4% Gum acacia orally. The other groups received following drugs in 4% Gum acacia suspension namely diclofenac sodium 4.5mg/kg and cetirizine 900µg/kg. The dose and route of administration is same as that of rat paw edema method.

All the rats were anaesthetized with ether. The dorsal skin was shaved and applied alcohol to maintain aseptic condition. On either side of midline of dorsal skin, four small
incisions of about 1 cm length were made. A curved forceps was passed through incisions to make subcutaneous pouch around it. Similarly four such pouches were made and sterilized rexin pellets were implanted into each pouch. (Photograph 3).

All the rats were treated with fixed dose of drugs (as mentioned above) once in every 24 hours for seven days including the day of implantation of pellets. The animals were provided with free access to food and water. During seven days, the rats were observed for any behavioral changes. On the 8th day, rats were sacrificed with ether anesthesia. The implanted pellets along with granulation tissue were removed. All the pellets were cleaned separately, extraneous tissue removed and dried by incubating in hot air oven at 60°C for 24 hrs. The pellets thus dried along with adherent granulation tissue were weighed and the weight of the granulation tissue formed was obtained by deducting the weight of rexin pellets before implantation. Then the mean weight of granulation tissue for each group was calculated. The difference in weight of granulation tissue of control and drug treated group was determined and percent inhibition was calculated by using the following formula.

\[ \text{Percent inhibition} = \frac{W_c - W_t}{W_c} \times 100 \]

Where,

- \( W_c \) = Weight of pellets in control group.
- \( W_t \) = Weight of pellets in drug treated group.

3. Study of mast cell count: From the control and treated groups of rats subcutaneous areolar tissue near the implanted pellet was carefully removed and thinly spread on a clean slide avoiding over stretching. The spread was fixed for 2 minutes in absolute alcohol and stained for 1 min in 0.1% aqueous solution of toluidine blue.

The microscopic study of subcutaneous spread collected from these animals of different groups is undertaken to find out the number of mast cells in 10 high power fields at random. Mean was calculated to find out S.D, S.E and P values and results were tabulated in Table 4.

**Statistical analysis:** Statistical analysis of experimental data was done by standard deviation (S.D), standard error (S.E) and P values.

**RESULTS:** The results obtained from the standard and test drugs are shown in Table 2, Photograph 1 & 2. The percent inhibition of edema in rats treated with Diclofenac sodium, Cetirizine hydrochloride is calculated with reference to the control group. The percent inhibition of edema at the end of 3 hours with Diclofenac sodium is 61.29% whereas Cetirizine dihydrochloride is 41.93%.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control Group</th>
<th>Standard Group</th>
<th>Test group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs</td>
<td>4% Gum Acacia</td>
<td>Diclofenac Sodium</td>
<td>Cetirizine</td>
</tr>
<tr>
<td>Edema Volume (ml)</td>
<td>Baseline</td>
<td>At the end of 3</td>
<td>Difference in volume</td>
</tr>
<tr>
<td>Rat</td>
<td>Baseline</td>
<td>At the end of 3</td>
<td>Difference in volume</td>
</tr>
</tbody>
</table>
Table 3: Effect of standard drug and test drug on rexin pellet granuloma method.

<table>
<thead>
<tr>
<th>Group (n=5)</th>
<th>Control Group</th>
<th>Standard Group</th>
<th>Test Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs</td>
<td>4% Gum Acacia</td>
<td>Diclofenac Sodium</td>
<td>Cetirizine hydrochloride</td>
</tr>
<tr>
<td>Rats (4 pellets/ rat)</td>
<td>Gain in weight of individual rexin pellet (mg)</td>
<td>Mean weight gain (mg)</td>
<td>Gain in weight of individual rexin pellet (mg)</td>
</tr>
<tr>
<td>1</td>
<td>18,16,14,17</td>
<td>16.25</td>
<td>5.5</td>
</tr>
<tr>
<td>2</td>
<td>20,17,16,14</td>
<td>16.75</td>
<td>6.5</td>
</tr>
<tr>
<td>3</td>
<td>20,18,15,17</td>
<td>17.5</td>
<td>5.5</td>
</tr>
<tr>
<td>4</td>
<td>18,15,16,17</td>
<td>16.50</td>
<td>5.0</td>
</tr>
<tr>
<td>5</td>
<td>20,17,16,15</td>
<td>17.0</td>
<td>6.25</td>
</tr>
<tr>
<td>Total Mean</td>
<td>16.80</td>
<td>5.65</td>
<td>7.55</td>
</tr>
<tr>
<td>Percentage inhibition of granulation tissue</td>
<td>--</td>
<td>66.36%</td>
<td>50.05%</td>
</tr>
<tr>
<td>Standard deviation</td>
<td>0.43</td>
<td>0.44</td>
<td>0.33</td>
</tr>
<tr>
<td>Standard error</td>
<td>0.19</td>
<td>0.20</td>
<td>0.15</td>
</tr>
</tbody>
</table>
The anti-inflammatory effect was judged by noting the percentage inhibition in granuloma formation was determined by weighing the rexin pellets 7 days after their implantation in the subcutaneous tissue are shown in Table 3. Diclofenac sodium has shown 66.36% and Cetirizine dihydrochloride 66.05% inhibition of granuloma formation. Net granuloma formation was calculated by subtracting initial weight of rexin pellet (9.25mg) from the weights noted.

Table 4: Mast cell count in control, standard and test group.

<table>
<thead>
<tr>
<th>Field nos.</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>Mean</th>
<th>S.D</th>
<th>S.E</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>13</td>
<td>9</td>
<td>3</td>
<td>18</td>
<td>21</td>
<td>20</td>
<td>11</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>12.0</td>
<td>5.88</td>
<td>1.86</td>
<td>--</td>
</tr>
<tr>
<td>Diclofenac sodium</td>
<td>10</td>
<td>10</td>
<td>9</td>
<td>10</td>
<td>15</td>
<td>16</td>
<td>6</td>
<td>10</td>
<td>7</td>
<td>6</td>
<td>9.9</td>
<td>3.21</td>
<td>1.02</td>
<td>&gt;0.10</td>
</tr>
<tr>
<td>Cetirizine dihydrochloride</td>
<td>5</td>
<td>7</td>
<td>12</td>
<td>8</td>
<td>8</td>
<td>11</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7.2</td>
<td>2.52</td>
<td>0.80</td>
<td>=0.05</td>
</tr>
</tbody>
</table>

Mast cells were counted in 10 fields at random under high power and results were shown in Table 4. There was a marginal reduction in mast cells (Cetirizine) mean 7.2.

**DISCUSSION:** The principle indications for the use of second generation H1 receptor antagonists are in the treatment of disease with inflammatory component like allergic rhinitis, conjunctivitis, idiopathic urticarial and diseases of allergic nature like hayfever, pollinosis, dermatographism and atopic eczema. There are established facts that state that histamine play a role as a mediator of inflammation.

The edema induced is mediated by histamine and 5HT during the 1st hour after which the increased vascular permeability is maintained by kinin release up to 2.5 hours. Thereafter up to 6 hours the mediator appears to be prostaglandins, release of which is closely associated with migration of leucocytes into the inflamed site. All the mediators appear to be dependent upon an intact complement system for their activation and release.

Cetirizine dihydrochloride has shown considerable anti-inflammatory activity in carrageenin induced rat paw edema. The reduction in the edema was measured at the end of 3 hours and found to be maximum.

This is the period during which prostaglandin release associated with migration of leucocytes takes place as a consequence of histamine release. There is an increase in polymorphonuclear leucocytes in carrageenin induced edema. Cetirizine might be reducing edema by decreasing the number of polymorphonuclear leucocytes which include eosinophils and neutrophils.

The mechanism by which cetirizine produces reduction in edema might be operating at 2 stages, namely 1.Release of histamine and its effects on H1 receptors. Eosinophil chemotaxis, infiltration of neutrophils and platelets were inhibited.

In the chronic study (rexin pellet method), formation of granuloma was minimum with cetirizine. As granuloma represents the exudative and proliferative phases of inflammation, the drugs under study might be acting at these levels thereby reducing the migration of eosinophil's, neutrophils and platelets. The other probable mechanism of cetirizine as an anti-inflammatory activity is by release of PGE2 from monocyte and macrophages which are...
predominant cells in chronic inflammation. One of the main substances released by the mast cells is histamine and since H1 receptor antagonists are being studied, a study on mast cell count has also been carried out to substantiate the results obtained in the chronic model. The H1 receptor antagonist cetirizine has shown anti-inflammatory effects in animal models and it has widest therapeutic window and the lowest potential for dose limiting sedation and cognitive impairment may offer the greatest therapeutic potential for its clinical use.

ACKNOWLEDGEMENT: My sincere thanks to Dr. Prashant Dass, Post-graduate student, Department of Pharmacology, M.R. Medical College, Gulbarga, for his help in the meticulous preparation of this manuscript.

REFERENCES:


Photograph 1: Control Photograph 2: Treated
(Carrageenin induced rat paw edema) (Edema suppressed feet)

Photograph 3: Implanted rexin pellets.
Photograph 4: Control group showing marginal reduction in number of mast cells.

Photograph 5: Standard group (Diclofenac) showing marginal reduction in number of mast cells.

Photograph 6: Test group (Cetirizine) showing significant reduction in number of mast cells.